DelveInsight’s “Obesity Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of obesity, historical and forecasted epidemiology as well as the obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.
Discover which therapies are expected to grab the Obesity Market Share @ Obesity Market Outlook
Key Takeaways from the Obesity Market Report
- The increase in Obesity Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
- In 2023, the United States accounted for the largest obesity market size (more than USD 2,000 Million).
- The leading Obesity Companies such as Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others.
- Promising Obesity Pipeline Therapies such as Mazdutide, orforglipron, Semaglutide oral, Survodutide (BI 456906), pemvidutide, and others.
Stay ahead in the Obesity Therapeutics Market with DelveInsight’s Strategic Report @ Obesity Market Size
Obesity Epidemiology Segmentation in the 7MM
The epidemiology section of Obesity offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Obesity Epidemiology trends @ Obesity Prevalence
Obesity Drugs Market
The Obesity Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying obesity are likely to uncover new therapeutic targets and further expand treatment options for patients.
Obesity Treatment Market Landscape
The Obesity treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of GLP-1, dual GLP-1/GIP, and next-generation incretin-based therapies has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Obesity treatment guidelines, visit @ Obesity Treatment Market Landscape
Obesity Market Outlook
The report’s outlook on the Obesity market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing obesity therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Obesity drug and late-stage pipeline therapy.
Obesity Drugs Uptake The drug chapter of the Obesity report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Obesity.
Major Obesity Companies
Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others.
Learn more about the FDA-approved drugs for Obesity @ Drugs for Obesity Treatment
Scope of the Obesity Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Obesity Companies- Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma, and others.
- Obesity Pipeline Therapies- Mazdutide, orforglipron, Semaglutide oral, Survodutide (BI 456906), pemvidutide, and others.
- Obesity Market Dynamics: Obesity Market Drivers and Barriers
- Obesity Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Obesity Drugs in development @ Obesity Clinical Trials Assessment
Table of Content
1. Key Insights
2. Report Introduction
3. Obesity Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Background and Overview
8. Obesity Epidemiology and Patient Population
9. Japan Epidemiology Scenario
10. Obesity Patient Journey
11. Obesity Marketed Therapies
12. Obesity Emerging Therapies
13. Obesity Market: The 7MM Analysis
14. Obesity Market Access and Reimbursement
15. Obesity KOL Views
16. SWOT Analysis
17. Obesity Unmet Needs
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
